Celularity Operating Margin from 2010 to 2024
| CELUW Stock | USD 0.02 0.0006 3.97% |
Check Celularity financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celularity's main balance sheet or income statement drivers, such as Depreciation And Amortization of 20.6 M, Interest Expense of 2.5 M or Selling General Administrative of 48.1 M, as well as many indicators such as Price To Sales Ratio of 1.84, Dividend Yield of 0.0 or PTB Ratio of 1.13. Celularity financial statements analysis is a perfect complement when working with Celularity Valuation or Volatility modules.
Celularity | Operating Margin |
Latest Celularity's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Celularity over the last few years. It is Celularity's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Celularity's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.84) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Celularity Operating Margin Regression Statistics
| Arithmetic Mean | (2.03) | |
| Coefficient Of Variation | (163.88) | |
| Mean Deviation | 2.77 | |
| Median | (0.000063) | |
| Standard Deviation | 3.32 | |
| Sample Variance | 11.01 | |
| Range | 8.4443 | |
| R-Value | (0.76) | |
| Mean Square Error | 4.98 | |
| R-Squared | 0.58 | |
| Significance | 0.001 | |
| Slope | (0.57) | |
| Total Sum of Squares | 154.19 |
Celularity Operating Margin History
About Celularity Financial Statements
Celularity investors use historical fundamental indicators, such as Celularity's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celularity. Please read more on our technical analysis and fundamental analysis pages.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey. Celularity Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 225 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.